BioSpace News Archive

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2022.

HAPPE Spine announces strategic new additions to its Board of Directors.

Actuate Therapeutics, Inc. announced today two poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

ProKidney LP, a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease and prevention of end-stage renal disease and need for dialysis, announced the appointment of Todd C. Girolamo as General Counsel.

Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will give an oral presentation in the Next Generation Kinase Inhibitors Summit.

Global Parents for Eczema Research and GlobalSkin - International Alliance of Dermatology Patient Organizations announced the winners of the “Big Ideas for Eczema Challenge” contest that generated worldwide interest and received 70 submissions from 11 countries.

Avera Health (Avera), and Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), today announced a strategic collaboration to advance comprehensive molecular profiling, enabling Avera Health’s providers and patients to benefit from data-driven insights that inform targeted cancer treatments.